Iowa Senate Bill SF2312

Iowa 2025-2026 Regular Session

• Introduced: 2/12/26
• Refer: 2/12/26

Caption

A bill for an act relating to manufacturers and distributors of 340B drugs.

Impact

The impact of SF2312 on state laws primarily concerns the responsibilities imposed on drug manufacturers and distributors regarding 340B drugs. By prohibiting any actions that could hinder the access of covered entities to these drugs, the bill effectively reinforces the existing federal 340B program’s intent at the state level. This alignment could bolster the financial health of affiliated healthcare entities and improve patient access to essential medications, particularly in low-income areas where resources are limited.

Summary

Senate File 2312 aims to regulate the acquisition and distribution of 340B drugs by defining key terms such as '340B drug', 'manufacturer', and 'distributor'. The bill specifies that manufacturers and distributors must not directly or indirectly deny or interfere with the acquisition of these drugs by covered entities, which include various healthcare providers that serve low-income patients. The protections outlined in the bill are designed to ensure that eligible entities can access discounted medications facilitated through the 340B program, thus supporting healthcare provision for underserved populations.

Contention

Notable points of contention surrounding SF2312 may arise from industry stakeholders, particularly pharmaceutical manufacturers who may view the bill as a restriction on their ability to control the distribution and pricing of 340B drugs. There are concerns regarding potential market distortions and economic implications if the manufacturers believe their autonomy is compromised. Discussions during hearings may reflect a clash between supporting public health initiatives and sustaining the economic viability of pharmaceutical enterprises.